Market capitalization | $16.07b |
Enterprise Value | $13.14b |
P/E (TTM) P/E ratio | 15.81 |
EV/FCF (TTM) EV/FCF | 14.64 |
EV/Sales (TTM) EV/Sales | 4.77 |
P/S ratio (TTM) P/S ratio | 5.83 |
P/B ratio (TTM) P/B ratio | 2.63 |
Revenue growth (TTM) Revenue growth | 25.04% |
Revenue (TTM) Revenue | $2.76b |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
17 Analysts have issued a United Therapeutics Corporation forecast:
17 Analysts have issued a United Therapeutics Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,756 2,756 |
25%
25%
|
|
Gross Profit | 2,451 2,451 |
25%
25%
|
|
EBITDA | 1,346 1,346 |
17%
17%
|
EBIT (Operating Income) EBIT | 1,279 1,279 |
16%
16%
|
Net Profit | 1,111 1,111 |
23%
23%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Head office | United States |
CEO | Martine Rothblatt |
Employees | 1,168 |
Founded | 1996 |
Website | www.unither.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.